Phase 2 Refractory Non-Hodgkin Lymphoma Clinical Trials
10 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–10 of 10 trials
Recruiting
Phase 1Phase 2
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLarge B-cell Lymphoma+1 more
Lyell Immunopharma, Inc.270 enrolled34 locationsNCT05826535
Recruiting
Phase 1Phase 2
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled65 locationsNCT06090539
Recruiting
Phase 2Phase 3
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 2
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Refractory Non-Hodgkin LymphomaB-cell LymphomaRelapsed Non Hodgkin Lymphoma+2 more
Rita Assi24 enrolled2 locationsNCT06484920
Recruiting
Phase 2
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Refractory Non-Hodgkin LymphomaRelapsed Non Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
Lazaros Lekakis22 enrolled1 locationNCT05260957
Recruiting
Phase 2
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma+4 more
Marcela V. Maus, M.D.,Ph.D.28 enrolled2 locationsNCT06550141
Recruiting
Phase 1Phase 2
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
High-grade B-cell LymphomaNon-Hodgkin LymphomaLymphoma+12 more
Estrella Biopharma, Inc.21 enrolled2 locationsNCT06343311
Recruiting
Phase 1Phase 2
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Multiple MyelomaNHLRefractory Non-Hodgkin Lymphoma+4 more
Indapta Therapeutics, INC.128 enrolled12 locationsNCT06119685
Recruiting
Phase 1Phase 2
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
Advanced Solid TumorsRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Non-Hodgkin Lymphoma
GI Cell, Inc.50 enrolled4 locationsNCT05880043